Friday, 16 October 2026European Markets

CNOVA Stock 17.93% Up Today

Loading stream...

(vianews) - the market ended the session with cnova (cnv.pa) rising 17.93% to €3.42 on wednesday, after two sequential sessions in a row of losses. cac 40 jumped 1.57% to €7,333.01, after three sequential sessions in a row of gains, on what was an all-around up trend exchanging session today.

cnova's last close was €2.90, 44.23% below its 52-week high of €5.20.

about cnova

cnova n.v. operates as an e-commerce company in france and western europe. the company offers home appliances, consumer electronics, computers, home furnishings, and leisure and personal goods through its cdiscount.com website. it also operates cdiscount voyages, a travel platform; cdiscount mobile for cell phone plans; cdiscount advertising, a digital marketing solution; octopia for turnkey marketplace solutions to retailers and e-merchants; and c-logistics for transportation and logistics services. the company was founded in 1998 and is headquartered in amsterdam, the netherlands. cnova n.v. is a subsidiary of casino, guichard-perrachon s.a.

earnings per share

as for profitability, cnova has a trailing twelve months eps of €-0.45.

revenue growth

year-on-year quarterly revenue growth declined by 29%, now sitting on 1.7b for the twelve trailing months.

yearly top and bottom value

cnova's stock is valued at €3.42 at 22:32 est, way below its 52-week high of €5.20 and way higher than its 52-week low of €2.00.

volatility

cnova's last week, last month's, and last quarter's current intraday variation average was a positive 3.96%, a negative 3.40%, and a positive 7.35%.

cnova's highest amplitude of average volatility was 5.66% (last week), 11.85% (last month), and 7.35% (last quarter).

volume

today's last reported volume for cnova is 4869 which is 139.73% above its average volume of 2031.

more news about cnova (cnv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com